Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib

BACKGROUND: Anlotinib significantly extended progression‐free survival (PFS) and overall survival (OS) in small‐cell lung cancer (SCLC) as third or later line treatment. METHODS: In this study, we retrospectively analyzed the efficacy and safety of anlotinib in the clinical practice and aimed to ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Boyu, Xin, Lingli, Hou, Qingxiang, Yang, Bo, Zhang, Jing, Qi, Xiaoguang, Wei, Yingtian, Hu, Yi, Xiong, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209577/
https://www.ncbi.nlm.nih.gov/pubmed/33960145
http://dx.doi.org/10.1002/cam4.3941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209577/
https://www.ncbi.nlm.nih.gov/pubmed/33960145
http://dx.doi.org/10.1002/cam4.3941

Ejemplares similares